Navigation Links
Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
Date:2/21/2012

WATERTOWN, Mass., Feb. 21, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that it has entered into an exclusive collaboration and license agreement with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. Enanta has received IND approval for EDP-239 from the FDA.

NS5A, a clinically validated target, is a non-structural viral protein that is essential to viral replication. Research efforts have shown that targeting NS5A gives rise to profound antiviral activity, and as a result, this protein has emerged as an important target for antiviral drug development. Enanta's NS5A program and intellectual property estate in the HCV field were derived from its internal drug discovery efforts.  EDP-239, Enanta's lead candidate targeting NS5A was most recently recognized on Windhover's list of the "Top Most Interesting Infectious Disease Projects to Watch".

Under the terms of the agreement, Enanta will receive an upfront payment of $34 million and is eligible to receive up to $406 million if certain clinical, regulatory, and commercial milestones are met. Enanta is also eligible to receive tiered double-digit royalties on worldwide sales of products, and retains co-detail rights in the United States. Novartis will be responsible for all costs associated with the development, manufacture and commercialization of EDP-239 and will fund Enanta's drug discovery efforts on certain additional compounds targeting NS5A.

"Novartis is a recognized leader in the field of HCV, and access to its global expertise combined with our shared vision for commercializing HCV therapies will support the successful development and commercialization of products targeting N
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
6. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
11. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a general corporate update in conjunction with its ... June 25 at 2:10 p.m. Pacific Time in ... meeting is as follows: 2:00 p.m. – 2:10 p.m. Annual ... April 26, 2013) 2:10 p.m. – 3:15 p.m. Corporate Presentation ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
(Date:6/17/2013)... June 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a preliminary prospectus supplement to its effective ... a similar filing with securities regulatory authorities in each of ... with a public offering of its common shares to raise ... The Company will also grant to the underwriters of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
... 2011 Endologix, Inc. (Nasdaq: ELGX ), ... announced the filing of its annual report on Form ... fourth quarter and full year 2010 financial results. ... to Endologix,s December 2010 acquisition of Nellix, Inc., the ...
... March 16, 2011 Golf fans can take a hands-on ... Scottsdale Healthcare Thompson Peak Hospital this Saturday during Scottsdale Healthcare ... Golf Club at JW Marriott Desert Ridge Resort & Spa ... Leading surgeons from greater Phoenix will be on hand ...
Cached Medicine Technology:Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized 2Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized 3Golf Fans Can Test Drive Surgery Robot at LPGA Tourney 2
(Date:6/18/2013)... the mammary gland appear to provide a crucial link ... and the subsequent development of breast cancer, researchers from ... issue of the journal Cancer Prevention Research . ... with an increased risk of certain types of aggressive ... social stress to cancer have been hard to identify. ...
(Date:6/18/2013)... University Hospitals Case Medical Center enrolled their first patients ... evaluating a novel, less-invasive procedure to help clear blockages ... year, more than 300,000 people in the United States ... artery. If left untreated, these blockages can slow or ... potentially disabling stroke, also known as a "brain attack." ...
(Date:6/18/2013)... Perlman has discovered a way to make phytosterol molecules ... consumed by humans, potentially opening the way to dramatic ... (#8,460,738) on the new process and composition was issued ... and cholesterol molecules in animals are highly similar and ... one another. When they mix in the gut of ...
(Date:6/18/2013)... of investigators co-led by Weill Cornell Medical College is ... research, similar to the kind of risk and benefit ... no dynamic research framework to systematically detect devices and ... may even be harmful," says co-lead investigator Dr. Art ... the June 18 issue of the British Medical ...
(Date:6/18/2013)... first computer guided fitness training system using a ... three winners of the LeWeb,13 London Startup Competition, ... The startup company, Genetrainer, building on University of ... Ralph Pethica and Julian Gough, Professor of Bioinformatics ... selected from over 350 startups to be one ...
Breaking Medicine News(10 mins):Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2Health News:Brandeis scientist invents anti-cholesterol process 2Health News:Tackling a framework for surgical innovation 2Health News:Tackling a framework for surgical innovation 3
... University of Cambridge have discovered a rare genetic disorder. ... who suffer no physical pain because of mutation ... are noticed to be numb to pain.Three related families ... , ,The research has been published by the ...
... a man made heart implanted inside him last ... have a heart beat! ,“Heartmate II”, the mechanical heart ... Nadia Giannetti in a three-hour surgery on Nov. 23, 2006.This device,is ... using a turbine balanced within a magnetic field. Before the surgery, ...
... Persons suffering from schizophrenia have greater chances of ... compared with those without mental// illness, according to ... of the Journal of General Internal Medicine. ... the larger puzzle of understanding the relationships between ...
... Karolinska Institutet, almost quarter of all mothers have problems ... many physical ailments, new mothers have better self-rated health ... ,In her thesis, Women’s health after childbirth, postgraduate ... to the question of how childbirth affects mothers’ physical ...
... has suggested that certain Christmas toys are not safe and ... out of the 15 that// were tested, turned out to ... of 85 decibels. ,Among the toys, the ... mechanical toy machine gun, a plastic tommy gun and a ...
... San Mateo Seniors quarantine 3 more medical facilities after the ... year than the// past. ,San Mateo County health ... already sickened dozens of people in a Belmont senior living ... doctors added that the outbreak is being reported more this ...
Cached Medicine News:Health News:Schizophrenics At Greater Risk Of Developing Chronic Diseases 2Health News:Exertion Incontinence - A Common Postnatal Problem 2Health News:Toy Story Turns Bitter-Christmas Toys, No Music to the Ears! 2Health News:Quarantine Hits 3 More Hospitals In San Mateo 2
The Genesis II total knee system defines the state of knee implants....
... Solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... StelKast's Proven Knee System is a long ... proven design. Available in both posterior stabilized ... Proven Knee System provides the flexibility needed ... standardization and ease of identification keeps the ...
... system was designed to enhance durability, ... surfaces, to minimize contact stress associated ... well balanced knee with normalized quadriceps ... Knee system allows maximum surgical flexibility ...
Medicine Products: